Your browser doesn't support javascript.
loading
Sensorineural hearing loss induced by gefitinib: A CARE-compliant case report and literature reviews.
Zhu, Bao-Chen; Yang, Wen-Hua; Huang, Mao; Wang, Jin-Gui; Liang, Yan; Lei, Zhen-Zhen; Zhang, Sha-Sha; Wang, Ying; Sun, Xiao-di; Gong, Ying; Xue, Chun-Miao; Hua, Guo-Dong.
Affiliation
  • Zhu BC; Department of Pharmacy, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
  • Yang WH; Department of Pharmacy, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
  • Huang M; Department of Respiratory, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
  • Wang JG; Department of Pharmacy, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
  • Liang Y; Department of Pharmacy, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
  • Lei ZZ; Department of Pharmacy, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
  • Zhang SS; Department of Pharmacy, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
  • Wang Y; Department of Pharmacy, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
  • Sun XD; Department of Pharmacy, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
  • Gong Y; Department of Pharmacy, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, China.
  • Xue CM; Department of Pharmacy, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
  • Hua GD; Department of Pharmacy, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
Medicine (Baltimore) ; 102(45): e36010, 2023 Nov 10.
Article in En | MEDLINE | ID: mdl-37960757
ABSTRACT
RATIONALE Gefitinib is a potent and selective orally active growth factor receptor (EGFR)-tyrosine kinase inhibitor that is commonly used to treat advanced non-small cell lung cancer patients with activating EGFR mutations. Hearing impairment with gefitinib was sparsely reported. In this report, we describe a case of sensorineural deafness associated with the administration of gefitinib, with a Naranjo score of 7. PATIENT CONCERNS An 81-year-old female was diagnosed with lung adenocarcinoma with bone metastasis and an EGFR-activating mutation. The patient was prescribed gefitinib tablets at a daily dose of 250 mg for lung adenocarcinoma treatment. However, the patient experienced moderate to severe bilateral sensorineural deafness, primarily in her right ear, after taking gefitinib. Following the cessation of gefitinib administration, the patient exhibited partial restoration of auditory function. Upon resuming the medication, she experienced a worsening of deafness. DIAGNOSES The otoscopic audiogram and hearing test indicated moderate to severe bilateral sensorineural deafness.

INTERVENTIONS:

The otolaryngologist recommended bilateral hearing aids to enhance hearing function.

OUTCOMES:

Throughout our follow-up period, the patient did not receive a hearing aid implant. LESSONS This article first reported the ototoxicity caused by gefitinib. While rare, our report highlights that gefitinib-induced sensorineural deafness is possible and its mechanisms are still unclear. This adverse reaction should be monitored closely during clinical application of gefitinib to improve patient outcomes.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Non-Small-Cell Lung / Deafness / Adenocarcinoma of Lung / Hearing Loss, Sensorineural / Lung Neoplasms Limits: Aged80 / Female / Humans Language: En Journal: Medicine (Baltimore) Year: 2023 Document type: Article Affiliation country: China

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Non-Small-Cell Lung / Deafness / Adenocarcinoma of Lung / Hearing Loss, Sensorineural / Lung Neoplasms Limits: Aged80 / Female / Humans Language: En Journal: Medicine (Baltimore) Year: 2023 Document type: Article Affiliation country: China